US › Healthcare

NRX Pharmaceuticals Inc (NRXP)

US · Healthcare · Biotechnology

$3.05-5.86%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.1M
Revenue YoY
+26600.0%
Net profit
$-1.4M
Profit YoY
+74.1%
EPS
$-0.04
EPS estimate
$-0.11
Net margin
-133.9%

EPS came in at -0.04 against a street estimate of -0.11 — a beat of 63.6%.

Key statistics

Market cap
$134.8M
Forward P/E
34.2
P/B
2.90
Book value
$-0.41
EPS (TTM)
$-1.04
52-week high
$5.05
52-week low
$1.62
50-day MA
$3.95
200-day MA
$2.78
Beta
2.19

Analyst view

Analysts rate NRX Pharmaceuticals Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $42.00.

Shareholding

Insiders
7.58%
Institutions
17.80%

Largest institutional holders

FundStake
B Group, Inc7.01%
Vanguard Capital Management, LLC2.71%
Commonwealth Equity Services, LLC1.06%
AdvisorShares Investments, LLC0.98%
Geode Capital Management, LLC0.72%
Vanguard Fiduciary Trust Co0.40%
Bleakley Financial Group LLC0.27%
BlackRock Inc0.23%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for NRX Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.